Markers of maternal cardiac dysfunction in pre-eclampsia and superimposed pre-eclampsia by Conti-Ramsden, Frances et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ejogrb.2019.04.034
Document Version
Early version, also known as pre-print
Link to publication record in King's Research Portal
Citation for published version (APA):
Conti-Ramsden, F., Gill, C., Seed, P. T., Bramham, K., Chappell, L. C., & McCarthy, F. P. (2019). Markers of
maternal cardiac dysfunction in pre-eclampsia and superimposed pre-eclampsia. European Journal of Obstetrics
and Gynecology and Reproductive Biology, 237, 151-156. https://doi.org/10.1016/j.ejogrb.2019.04.034
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 23. May. 2019
                             Elsevier Editorial System(tm) for European 
Journal of Obstetrics & Gynecology and Reproductive Biology 
                                  Manuscript Draft 
 
 
Manuscript Number: EJOGRB-19-19302 
 
Title: Markers of maternal cardiac dysfunction in pre-eclampsia and 
superimposed pre-eclampsia  
 
Article Type: Full Length Article 
 
Section/Category: Maternal-Fetal Medicine 
 
Keywords: Pregnancy; pre-eclampsia; glycogen phosphorylase isoenzyme BB 
(GPBB); brain natriuretic peptide (BNP). 
 
Corresponding Author: Dr. Frances Conti-Ramsden, MBBS MRCP 
 
Corresponding Author's Institution: King's College London 
 
First Author: Frances Conti-Ramsden, MBBS MRCP 
 
Order of Authors: Frances Conti-Ramsden, MBBS MRCP; Carolyn Gill, PhD; 
Paul T Seed, MSc CStat; Kate Bramham, PhD; Lucy C Chappell, PhD; Fergus P 
McCarthy, PhD 
 
Abstract: Objectives: To determine whether glycogen phosphorylase 
isoenzyme B (GPBB) and/or brain natriuretic peptide (BNP) concentrations 
are elevated in pre-eclampsia and superimposed pre-eclampsia (SPE), 
demonstrating cardiac ischaemia and strain.  
 
Study design: A nested case-control study was performed using samples and 
clinical data available from a prospective pregnancy cohort. Four groups 
were selected: healthy pregnant controls (n=21), pre-eclampsia (n=19), 
pre-existing chronic hypertension (CHT) and/or chronic kidney disease 
(CKD) without (n=20) or with superimposed pre-eclampsia (SPE) (n=19). 
Plasma samples were taken at time of disease or the third trimester in 
controls.  
 
Results: There was no significant difference in GPBB plasma 
concentrations between controls and pre-eclampsia (geometric mean (GM) 
[95% CI]: 4.74 [2.54-8.84] ng/mL vs 5.01 [2.58-9.74] ng/mL, p=0.90)), or 
between CHT and/or CKD and SPE (GM [95% CI]: 9.49 [4.93-18.25] ng/mL vs 
10.24 [5.27-19.92] ng/mL, p=0.87). BNP plasma concentrations were 
significantly raised in women with pre-eclampsia compared to controls (GM 
[95% CI]: 31.83 [20.18-50.22] pg/mL vs 11.33 [7.34-17.51] pg/mL, 
p=0.001). Women with CKD, but not CHT, who developed SPE had elevated BNP 
concentrations. There were no significant differences in BNP 
concentration between women with comorbidity (CHT and/or CKD) and 
controls.  
 
Conclusions: GPBB has a limited role as a biomarker in hypertensive 
disorders of pregnancy. BNP concentrations were elevated in pre-eclampsia 
compared to controls. This suggests cardiac strain at the time of pre-
eclampsia. Further studies are needed to examine whether BNP can identify 
women at increased risk of cardiovascular disease. 
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Objectives: To determine whether glycogen phosphorylase isoenzyme B (GPBB) and/or 38 
brain natriuretic peptide (BNP) concentrations are elevated in pre-eclampsia and 39 
superimposed pre-eclampsia (SPE), demonstrating cardiac ischaemia and strain.  40 
Study design: A nested case-control study was performed using samples and clinical data 41 
available from a prospective pregnancy cohort. Four groups were selected: healthy 42 
pregnant controls (n=21), pre-eclampsia (n=19), pre-existing chronic hypertension (CHT) 43 
and/or chronic kidney disease (CKD) without (n=20) or with superimposed pre-eclampsia 44 
(SPE) (n=19). Plasma samples were taken at time of disease or the third trimester in 45 
controls.  46 
Main outcome measures: Plasma concentrations of GPBB and BNP.  47 
Results: There was no significant difference in GPBB plasma concentrations between 48 
controls and pre-eclampsia (geometric mean (GM) [95% CI]: 4.74 [2.54-8.84] ng/mL vs 5.01 49 
[2.58-9.74] ng/mL, p=0.90)), or between CHT and/or CKD and SPE (GM [95% CI]: 9.49 [4.93-50 
18.25] ng/mL vs 10.24 [5.27-19.92] ng/mL, p=0.87). BNP plasma concentrations were 51 
significantly raised in women with pre-eclampsia compared to controls (GM [95% CI]: 31.83 52 
[20.18-50.22] pg/mL vs 11.33 [7.34-17.51] pg/mL, p=0.001). Women with CKD, but not CHT, 53 
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who developed SPE had elevated BNP concentrations. There were no significant differences 54 
in BNP concentration between women with comorbidity (CHT and/or CKD) and controls.  55 
Conclusions: GPBB has a limited role as a biomarker in hypertensive disorders of pregnancy. 56 
BNP concentrations were elevated in pre-eclampsia compared to controls. This suggests 57 
cardiac strain at the time of pre-eclampsia. Further studies are needed to examine whether 58 
BNP can identify women at increased risk of cardiovascular disease. 59 
 60 
Keywords: Pregnancy, pre-eclampsia, glycogen phosphorylase isoenzyme BB (GPBB), brain 61 
natriuretic peptide (BNP). 62 
 63 
Highlights  64 
 Glycogen phosphorylase isoenzyme B is not a useful biomarker in pre-eclampsia 65 
 Brain natriuretic peptide (BNP) concentration is elevated in pre-eclampsia  66 
 BNP concentration in SPE may be influenced by underlying comorbidity 67 
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INTRODUCTION 69 
Women who experience hypertensive disorders of pregnancy have an increased risk of 70 
developing cardiovascular diseases including hypertension, stroke, and ischaemic heart 71 
disease later in life.1–3 This risk is evident shortly after an affected pregnancy and persists for 72 
decades.4 The mechanism underlying this association is not known, particularly whether 73 
women who develop hypertensive disorders are at higher risk pre-pregnancy and pregnancy 74 
unmasks their cardiovascular risk, or whether hypertensive disorders of pregnancy are an 75 
index event causing cardiovascular damage.5 In keeping with the latter, it is plausible that 76 
the pathophysiological changes of pre-eclampsia, namely ischaemia and endothelial 77 
dysfunction,6 cause irreversible cardiovascular impairment which contributes to the adverse 78 
cardiovascular outcomes later in life in these women.  79 
 80 
GPBB is found in human heart and brain tissue and is an early marker of myocardial 81 
ischaemia, rising rapidly within the first hour of onset of chest pain in acute coronary 82 
syndromes.7–12 BNP is primarily secreted by the left ventricle in response to cardiac chamber 83 
wall stretch as a result of systolic or diastolic dysfunction,13–17 and concentrations have been 84 
shown to increase with greater levels of cardiac damage in the context of heart failure.18 We 85 
hypothesised that subclinical cardiac ischaemia and dysfunction as demonstrated by 86 
elevated GPBB and BNP concentrations respectively occurs in women with pre-eclampsia 87 
and superimposed pre-eclampsia compared to controls and women with pre-existing 88 
chronic disease (chronic hypertension or chronic kidney disease). To investigate this, we 89 
measured concentrations of markers of cardiac ischaemia and strain: glycogen 90 
phosphorylase isoenzyme B (GPBB) and brain natriuretic peptide (BNP), at time of disease in 91 
women with pre-eclampsia or superimposed pre-eclampsia compared to controls. 92 
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 93 
METHODS 94 
Study design 95 
A nested case-control study was performed using samples and clinical data available from a 96 
pregnancy cohort, full details of which have been published elsewhere.19 In brief, the 97 
PEACHES study investigated predictive and diagnostic biomarkers for pre-eclampsia in 98 
women with pre-existing disease (chronic kidney disease (CKD) or chronic hypertension 99 
(CHT)), with a comparator control group also recruited. Between June 2009 and September 100 
2013, pregnant women with chronic kidney disease (CKD) or chronic hypertension (CHT) and 101 
healthy controls from two academic health science centres were prospectively enrolled 102 
between 20+0 and 36+6 weeks’ gestation. All participants completed written informed 103 
consent. Venous blood was drawn in EDTA tubes between one and four times during 104 
pregnancy, and samples (plasma and serum) were centrifuged at 1,400 x g for 10 minutes at 105 
4°C then stored at -80°C. Outcome data were recorded by case note review following 106 
delivery. Definitions were based on the International Society for Study of Hypertension in 107 
Pregnancy guidelines,20 and are available in Supplementary Table 1. Ethical approval was 108 
given by the National Research Ethics Service (11/LO/1776). All study procedures were 109 
performed in line with the Declaration of Helsinki.  110 
 111 
We selected four groups of pregnant women from the study: healthy women who did not 112 
develop pre-eclampsia (control group), women without pre-existing disease who developed 113 
pre-eclampsia (pre-eclampsia group), women with CKD and/or CHT who did not develop 114 
pre-eclampsia (CKD and/or CHT group), and women with CKD or CHT who developed 115 
superimposed pre-eclampsia (superimposed pre-eclampsia group). Samples assayed for 116 
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GPBB and BNP concentration were taken either at time of disease (pre-eclampsia and 117 
superimposed pre-eclampsia), or during the third trimester in controls.  118 
 119 
Assay analyses 120 
Plasma samples were assayed for GPBB concentration using Diagenics Dianeonatal® 121 
Glycogen phosphorylase Isoenzyme BB (GP-BB)-ELISA in-vitro diagnostic device kits (an 122 
Enzyme-linked immunosorbed assay for quantitative detection of GP-BB in human plasma), 123 
in line with the manufacturer’s instructions. All assays were run in duplicate in a blinded 124 
randomised manner. Intra-assay coefficients of variation were 9.1% and 3.5%, and inter-125 
assay coefficient of variation was 1.3%.   126 
 127 
The Alere Triage® CardioRenal assay was used to assay BNP concentration in line with the 128 
manufacturer’s instruction in a blinded randomised manner. It is a point of care 129 
fluorescence immunoassay which uses fluorescently labelled recombinant murine 130 
monoclonal antibodies. The assay specifically quantifies BNP concentration between the 131 
range 5-5000 pg/mL. The coefficient of variation on plasma controls were determined from 132 
the manufacturers leaflet and were 9.2% and 13.9% at concentrations of 78 and 3450 pg/mL 133 
respectively. 134 
 135 
Statistical analysis 136 
Data analysis was performed in Stata versions 14.2-15.1 (StataCorp, College Station, Texas). 137 
GPBB and BNP concentrations were compared between main groups, combined groups and 138 
subgroups. Standard distribution plots were used to assess normality of data and 139 
logarithmic transformation was applied for formal testing of differences using linear 140 
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 8 
regression of the transformed values with group differences expressed as ratios of the 141 
geometric mean (GM). Due to censoring of values less than the lower limit of detection or 142 
above the upper limit, interval regression was used.21 Demographic characteristics and 143 
pregnancy outcomes between groups were compared using unpaired t-tests and Chi-144 
squared tests. 145 
 146 
RESULTS 147 
Baseline variables and pregnancy outcomes 148 
Seventy-nine women were identified from the PEACHES cohort: 21 controls, 19 with pre-149 
eclampsia, 20 with CHT and/or CKD and 19 with superimposed pre-eclampsia (SPE). The 150 
demographic and clinical characteristics and pregnancy outcomes of the four groups are 151 
described in Tables 1 and 2. Compared to controls, women who developed pre-eclampsia 152 
had on average a higher body mass index (BMI), and were more likely to have a preterm 153 
delivery, lower birthweight infants, and more likely to deliver by Caesarean section. 154 
Compared to women with pre-existing CHT and/or CKD, women who developed SPE were 155 
also more likely to have preterm delivery, lower birthweight infants, and deliver by 156 
Caesarean section.  157 
 158 
GPBB plasma concentrations in pre-eclampsia and superimposed pre-eclampsia  159 
No significant difference was observed in GPBB plasma concentrations between the pre-160 
eclampsia and control groups (geometric mean (GM) [95% CI]: 5.01 [2.58-9.74] ng/mL  vs  161 
4.74 [2.54-8.84] ng/mL; ratio GMs 1.06 [0.43-2.63], p=0.90), or between the SPE and CHT 162 
and/or CKD groups (when pooled across high-risk categories) (GM [95% CI]: 10.24 [5.27-163 
19.92] ng/mL  vs 9.49 [4.93-18.25] ng/mL; ratio GMs 1.08 [0.42-2.74], p=0.87). A box plot of 164 
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 9 
GPBB concentration in the sub-groups is shown in Figure 1. Comparison of GPBB 165 
concentrations in women with comorbidities against controls was undertaken. Considering 166 
women with CHT, CKD and CHT and CKD as separate groups, only women with CHT had 167 
elevated GPBB concentrations compared to controls (geometric mean (GM) [95% CI]: 19.84 168 
[6.19-63.58] ng/mL  vs 4.74 [2.54-8.84] ng/mL; ratio GMs 4.19 [1.12-15.70], p = 0.034); 169 
however, this difference was no longer significant once adjustments were made for 170 
maternal age, ethnicity and BMI (ratio GMs 3.54 [0.87-14.39], p = 0.077). In addition, in the 171 
regression model adjusted for maternal age, BMI, ethnicity, and pre-eclampsia neither CKD 172 
(p=0.172) nor CHT (p=0.099) diagnoses considered as separate variables had a significant 173 
effect on GPBB concentration. 174 
 175 
Box plots for pooled groups are shown in Supplementary Figure 1. Adjusting for maternal 176 
age, ethnicity and BMI in regression models did not alter results (pre-eclampsia v control: 177 
ratio GMs 1.31 [0.51-3.32], p=0.57, SPE v CHT and/or CKD: ratio GMs 1.31 [0.53-3.22], 178 
p=0.56). Ethnicity was noted to be highly significant in this model. Black women had a 179 
relative reduction in GPBB concentration of -68.9% (95% confidence interval -85.7% to -180 
32.5%) compared to white women after adjustment for maternal age, BMI, comorbidity and 181 
pre-eclampsia status.  182 
 183 
BNP plasma concentration in pre-eclampsia and superimposed pre-eclampsia 184 
BNP plasma concentrations were significantly raised in the pre-eclampsia group compared 185 
to the control group (GM [95% CI]: 31.83 [20.18-50.22] pg/mL vs 11.33 [7.34-17.51] pg/mL; 186 
ratio GMs 2.81 [1.50-5.27], p=0.001). This result became more significant after adjustment 187 
for maternal age, ethnicity and BMI (ratio GM 3.39 [1.78-6.47], p<0.001). No significant 188 
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differences were observed between the pooled groups of superimposed pre-eclampsia and 189 
CHT and /or CKD groups (GM [95% CI]: 20.66 [12.40-34.44] pg/mL vs 16.06 [9.83-26.23] 190 
pg/mL; ratio GMs 1.29 [0.63-2.61], p=0.486), and this was unchanged by adjusting for 191 
maternal age, ethnicity and BMI (ratio GMs 1.28 [0.66-2.50], p=0.461). A box plot of BNP 192 
concentration in the sub-groups is shown in Figure 2, with pooled groups shown in 193 
Supplementary Figure 2. When women with CHT, CKD and CHT/CKD were considered 194 
individually, none had significantly elevated BNP concentrations compared to controls (ratio 195 
GMs [95% CI] of CHT v control: 0.99 [0.40-2.49]; p = 0.989, CKD v control: 1.37 [0.57-3.28]; 196 
p=0.484, CHT and CKD v control: 2.00 [0.84-4.76]; p=0.116), and these findings were not 197 
altered by adjustment for maternal age, BMI and ethnicity.  198 
 199 
Interval regression adjusted for maternal age, ethnicity and BMI was performed. Adjusted 200 
ratios of the geometric mean for the subgroups are shown in Table 3. In the CKD subgroup 201 
and CKD and CHT subgroup SPE was associated with elevated BNP concentrations (but not 202 
in the CHT group). Interaction tests were performed between pre-eclampsia diagnosis and 203 
CKD (p = 0.44) and between pre-eclampsia diagnosis and CHT (p <0.01), consistent with 204 
these results. CKD stage had no effect on BNP concentration in women with CKD (p=0.676, 205 
with adjustment for maternal age, BMI, ethnicity, presence of SPE or comorbid CHT). 206 
 207 
DISCUSSION 208 
In this study BNP concentrations were elevated in cases of pre-eclampsia compared to 209 
controls. BNP concentrations were also elevated in women with CKD with or without co-210 
existent CHT but not CHT alone who had superimposed pre-eclampsia. GPBB concentrations 211 
were not elevated in pre-eclampsia or superimposed pre-eclampsia compared with controls, 212 
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but were lower in Black compared to White women. Our findings suggest cardiac strain at 213 
the time of pre-eclampsia, and evidence of differences in cardiac pathophysiology during 214 
SPE in women with CKD compared to CHT. We found no evidence of subclinical cardiac 215 
ischaemia as demonstrated by GPBB concentration in pre-eclampsia or SPE and a limited 216 
role for the use of GPBB in the evaluation of hypertensive disorders of pregnancy.  217 
 218 
The limitations of our study include the relatively small numbers per group, which may have 219 
limited the power to detect differences between groups. Although there were differences in 220 
timing of samples between groups (time of disease for pre-eclampsia/SPE compared to third 221 
trimester for controls) which could also have attributed to variability in GPBB and BNP 222 
concentrations and confounded the results, data reported by Lee et al., 22 on 32 pregnant 223 
women with serial GPBB measures in each trimester reported no differences in GPBB 224 
concentration with advancing gestation. Similarly, serial BNP sampling in normal 225 
pregnancies have reported no variation with advancing gestational age.23  226 
 227 
Our study differs with the findings of Lee et al., 22 which reported GPBB concentrations 228 
being elevated in preterm pre-eclampsia compared to gestational-age matched controls, 229 
and McCarthy et al., 24 which reported GPBB concentrations were elevated in women with 230 
term pre-eclampsia and small-for-gestational age pregnancies at time of disease compared 231 
to controls. All three studies used a Diagenics ELISA assay although the exact assay used 232 
differed between studies (Dianeonatal in our study, Diacordon in study by McCarthy et al., 233 
not specified in study by Lee et al.). Another potential explanation for the difference in 234 
findings is that the demographic characteristics of the women included in these studies 235 
differs; the SCOPE cohort reported by McCarthy et al. was 100% White, the study 236 
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population in Lee et al. was approximately 90% Black, whilst we had a mixed population. 237 
However, whilst we did demonstrate that GPBB levels are lower in Black than White 238 
women, adjusting for ethnicity did not alter our findings.  239 
 240 
Several small studies have investigated concentrations of cardiac troponin I, (the most 241 
widely used marker of cardiac ischaemia in clinical practice), in women with pre-eclampsia 242 
with conflicting results.25,26 In a systematic review, five out of nine studies found cardiac 243 
troponin concentrations were raised in pre-eclampsia, but studies were of poor quality.27 244 
Our study suggests there is no significant subclinical cardiac ischaemia at the time pre-245 
eclampsia; however, further high quality studies combining biomarkers and 246 
echocardiographic variables are necessary.  247 
 248 
Our finding of elevated BNP concentration in pre-eclampsia compared to controls is 249 
consistent with other small studies. In a systematic review of BNP concentrations in women 250 
with pre-eclampsia compared to pregnant controls the majority of studies reported raised 251 
BNP concentrations although small sample size, heterogeneity and poor study quality 252 
precluded a quantitative analysis.28 Our study is the first to report BNP concentrations in 253 
women with superimposed pre-eclampsia, and whilst there were no significant differences 254 
between groups overall, in a post-hoc subgroup analysis BNP concentrations were 255 
significantly elevated in women with CKD or CKD and CHT who developed pre-eclampsia. 256 
Given the small numbers in our study this result must be interpreted with caution; however, 257 
it is plausible that cardiac pathophysiology in SPE may differ depending on the underlying 258 
comorbidity and that women with CHT alone have a wider spectrum of disease, including 259 
those with minimal cardiac dysfunction.  260 
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 261 
The clinical significance of the raised BNP concentrations in our study are uncertain as we 262 
did not have access to vascular function measures or echocardiography as part of the 263 
original study. In a study comparing 40 women with pre-eclampsia to 35 normotensive 264 
controls mean (standard deviation) BNP concentration was 37.1 (10.0) pg/mL in the pre-265 
eclampsia group compared to 21.5 (8.0) pg/mL in controls, and there was a linear 266 
association between BNP concentration and left ventricular end-diastolic volume.29 Similar 267 
associations between BNP concentration and echocardiographic features of left ventricular 268 
diastolic dysfunction and depression of cardiac output are suggested by other small 269 
studies.28 Therefore larger studies and studies that prospectively evaluate the relationship 270 
between cardiac biomarkers and adverse cardiovascular outcomes following hypertensive 271 
disorders of pregnancy are warranted.  272 
 273 
CONCLUSION 274 
Currently there is insufficient evidence to support GPBB testing as a useful diagnostic or 275 
prognostic test in pre-eclampsia. We have replicated findings from other small studies that 276 
BNP concentrations are elevated in pre-eclampsia, suggesting subclinical cardiac strain at 277 
time of disease. Larger studies are required to confirm this finding and investigate whether 278 
BNP and other cardiac biomarkers at time of disease in pre-eclampsia and superimposed 279 
pre-eclampsia can be used to identify women at high risk of long-term cardiovascular 280 
disease.  281 
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Table 1. Maternal characteristics of control, pre-eclampsia, chronic hypertension (CHT) and/or chronic kidney disease (CKD) and superimposed 
pre-eclampsia 
groups.  
Abbreviations: 
IQR = 
interquartile 
range.  
 
 
 Controls Pre-eclampsia p-value CHT and/or 
CKD 
Superimposed 
pre-eclampsia 
p-value 
Number of women 21 19  20 19  
Demographic variables       
Age, y, median (IQR) 29 (24-33) 29 (25-36) 0.50 35 (26-38.5) 32 (28-36) 0.61 
BMI, kg/m2, median (IQR) 22.6 (21.3-27.1) 29.1 (24.7-32.4) 0.03 28.3 (24.6-32.0) 28.7 (23.3-34.7) 0.57 
Nulliparous, n (%) 16 (76.2) 14 (73.7) 0.86 10 (50.0) 9 (47.4) 0.87 
Ethnicity 
White ethnicity, n (%) 
Black ethnicity, n (%) 
Asian ethnicity, n (%) 
Other ethnicity, n (%) 
 
15 (71.4) 
5 (23.8) 
1 (4.8) 
0 (0) 
 
7 (36.8) 
9 (47.4) 
1 (5.3) 
2 (10.5) 
 
 
0.08 
 
11 (55.0) 
7 (35.0) 
0 (0) 
2 (10.0) 
 
7 (36.8) 
8 (42.1) 
1 (5.3) 
3 (15.8) 
 
 
0.47 
Smoking status 
Current smoking, n (%) 
Quit smoking, n (%) 
Never smoked, n (%) 
 
3 (14.3) 
1 (4.8) 
17 (81.0) 
 
1 (5.3) 
2 (10.5) 
16 (84.2) 
 
 
0.56 
 
1 (5.0) 
1 (5.0) 
18 (90.0) 
 
2 (10.5) 
3 (15.8) 
14 (73.7) 
 
 
0.44 
Medical history       
Pre-gestational diabetes 
mellitus, n (%) 
0 (0) 1 (5.3) 0.29 1 (5.0) 2 (10.6) 0.52 
Chronic hypertension, n (%) 0 (0) 0 (0) - 13 (65.0) 15 (78.9) 0.33 
Chronic kidney disease 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
0 (0) 
- 
- 
- 
- 
0 (0) 
- 
- 
- 
- 
 
 
- 
14 (70.0) 
8 (40.0) 
5 (25.0) 
1 (5.0) 
0 (0) 
8 (42.1) 
5 (26.3) 
1 (12.5) 
1 (12.5) 
1 (12.5) 
0.08 
Table
Table 2. Pregnancy outcomes of control, pre-eclampsia, chronic hypertension (CHT) and/or chronic kidney disease (CKD) and superimposed 
pre-eclampsia groups. Abbreviations: IQR = interquartile range, SGA = small for gestational age.  
 Controls Pre-eclampsia p-value CHT and/or 
CKD 
Superimposed 
pre-eclampsia 
p-value 
Number of women 21 19  20 19  
Neonatal outcomes       
Gestation at delivery, wk, median 
(IQR) 
40.3  
(39.9-41.0) 
37.6  
(34.7-38.3) 
<0.01 39.0  
(38.4-40.1) 
36.6  
(34.1-38.1) 
<0.01 
Preterm delivery <37/40, n (%) 1 (4.8) 8 (42.1) <0.01 1 (5.0) 10 (52.6) <0.01 
Preterm delivery <34/40, n (%) 0 (0.0) 2 (10.5) 0.13 0 (0) 3 (15.8) 0.06 
Intrauterine death, n (%) 0 (0) 0 (0) - 0 (0) 0 (0) - 
Birth weight, g, median (IQR) 3300  
(3000-3620) 
2400  
(1970-3120) 
<0.01 3190  
(3055-3395) 
2500  
(2000-3000) 
<0.01 
SGA (<10th customized birth weight 
centile) 
5 (23.8) 7 (36.8) 0.37 3 (15.0) 8 (42.1) 0.06 
SGA (<3rd customized birth weight 
centile) 
0 (0) 3 (15.8) 0.06 2 (10.0) 4 (21.1) 0.34 
Mode of delivery       
Spontaneous vaginal delivery, n (%) 19 (90.5) 4 (21.1) <0.01 6 (30.0) 1 (5.3) 0.04 
Assisted vaginal delivery, n (%) 1 (4.8) 2 (10.5) 0.49 4 (20.0) 1 (5.3) 0.17 
Caesarean delivery, n (%) 1 (4.8) 13 (68.4) <0.01 10 (50.0) 17 (89.5) <0.01 
GPBB and BNP sampling       
Gestational age at sampling, weeks, 
median (IQR) 
34.4  
(32.6-37.4) 
36.0  
(33.7-37.3) 
0.15 37.1  
(34.3-37.8) 
33.0 
(26.9-34.9) 
<0.01 
 
Table
Table 3. BNP concentrations with ratio of geometric means (GM) adjusted for maternal age, ethnicity and BMI comparing control, chronic 
hypertension (CHT), chronic kidney disease (CKD), and CHT and CKD groups with and without pre-eclampsia.  
 BNP concentration (ng/mL)   
Subgroup No (S)PE  
(GM [95% C.I.]) 
(S)PE  
(GM [95% C.I.]) 
 Adjusted ratio of GM 
[95% C.I.] 
p-value 
Controls (n=21) 11.3 [7.34-17.5] 31.8 [20.2-50.2] 3.39 [1.78-6.47] <0.001 
CHT (n=17) 11.3 [5.02-25.3] 9.74 [5.20-18.3] 0.39 [0.11-1.48] 0.168 
CKD (n=11) 15.5 [7.26-33.1] 98.0 [36.4-264] 9.48 [4.90-18.3] <0.001 
CHT and CKD (n=11) 22.7 [10.7-48.0] 31.3 [11.6-84.3] 3.30 [2.09-5.19] <0.001 
 
Table
Figure 1. Box plots with overlaid log values of GPBB plasma concentration (ng/mL) in control, chronic hypertension (CHT), chronic kidney 
disease (CKD), CHT and CKD, pre-eclampsia (PE), and superimposed pre-eclampsia (SPE) groups. 
 
Figure
Figure 2. Box plots with overlaid log values of BNP plasma concentration (pg/mL) in control, chronic hypertension (CHT), chronic kidney 
disease (CKD), CHT and CKD, pre-eclampsia (PE), and superimposed pre-eclampsia (SPE) groups. 
 
Figure
Supplementary Table 1: Definitions for study entry into PEACHES cohort.  
Definition Criteria 
Healthy control 
women 
 No risk factors for pre-eclampsia 
 No history of pre-eclampsia, hypertension, diabetes, renal disease, connective tissue disease or anti-
phospholipid antibody syndrome  
 Systolic blood pressure <140mmHg  
 Diastolic blood pressure <90mmHg  
 No protein on dipstick analysis of midstream urine 
 Not in labour 
Gestational 
Hypertension 
 Previously normotensive 
 Two recordings of systolic blood pressure ≥140mmHg or diastolic blood pressure ≥ 90mmHg greater 
than 4 hours apart  
 After 20 weeks’ gestation  
 Not in labour 
Pre-eclampsia  Gestational Hypertension 
AND 
 Proteinuria of >300mg protein over 24 hours, (or protein:creatinine ratio of >30mg/mmol); 
Superimposed pre-
eclampsia 
Hypertension 
already present 
  New onset of proteinuria >300mg protein over 24 hours, (or protein:creatinine ratio of  
>30mg/mmol); 
OR 
Additional features – severe persistent right upper quadrant pain or epigastric pain unresponsive to 
mediation or alanine transaminase > 71U/l or platelet count <100,000/µl or pulmonary oedema or new 
onset cerebral or visual disturbance 
Superimposed pre-
eclampsia 
Proteinuria already 
present 
 Two recordings of systolic blood pressure ≥140mmHg or diastolic blood pressure ≥ 90mmHg greater 
than 4 hours apart  
OR 
 Additional features as listed above 
Superimposed pre-
eclampsia 
 Development of severe hypertension (Systolic blood pressure ≥160mmHg or diastolic blood 
pressure ≥110mmHg)  
Figure
Hypertension and 
proteinuria already 
present 
AND 
 Greater than two fold increase in proteinuria above 300mg protein over 24 hours, (or 
protein:creatinine ratio of >30 mg/mmol); 
OR 
Additional features as listed above 
Primary 
Hypertension 
 Maternal diastolic blood pressure of 90mmHg or more before 20 weeks’ gestation in the current 
pregnancy 
OR 
 Taking antihypertensive agents before 20 weeks’ gestation  
OR 
 Taking antihypertensives prior to pregnancy  
 
 Secondary causes of hypertension excluded 
Chronic 
Hypertension 
 Primary or secondary causes of hypertension 
Chronic Kidney 
Disease 
 According to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines pre-pregnancy 
{Guidelines,  #50302}  
OR 
 Persistent proteinuria (>1+ or 30mg/mmol (protein creatinine ratio) before 20 weeks’ gestation  
OR  
 Any recorded serum creatinine >70μmol before 20 weeks’ gestation without risk factors for acute 
kidney injury; 
Exclusion  Women < 18 years old or >50 years old 
 Inability or unwillingness to give informed consent 
 Known HIV, Hepatitis B or C positive 
 Multi-fetal Pregnancy 
 
 
  
Supplementary Figure 1. Box plots with overlaid log values of GPBB plasma concentration (ng/mL) in control, chronic hypertension (CHT) 
and/or chronic kidney disease (CKD), pre-eclampsia (PE) and superimposed pre-eclampsia (SPE) groups. 
 
Supplementary Figure 2. Box plots with overlaid log values of BNP plasma concentration (pg/mL) in control, chronic hypertension (CHT) 
and/or chronic kidney disease (CKD), pre-eclampsia (PE) and superimposed pre-eclampsia (SPE) groups. *p value <0.05. 
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exposure, follow-up, and data collection 
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and control selection. Give the rationale for the choice of cases and controls 
(b) For matched studies, give matching criteria and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) If applicable, explain how matching of cases and controls was addressed 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
Outcome data 15* Report numbers in each exposure category, or summary measures of exposure 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
Checklist
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Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 
 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, 
for the original study on which the present article is based 
 
*Give information separately for cases and controls. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
